open access

Vol 58, No 3 (2020)
Original paper
Submitted: 2020-03-19
Accepted: 2020-09-13
Published online: 2020-09-22
Get Citation

Wilms’ tumor 1 antigen immunoreactivity in epithelial ovarian cancer — diagnostic and prognostic value

Elzbieta Zarychta1, Katarzyna Lepinay1, Sebastian Szubert1, Jakub Jozwicki2, Jan Misiak3, Anna A. Brozyna4, Katarzyna Kosinska-Kaczynska1, Agnieszka Lewandowska1, Ewa Malicka1, Adrianna Makarewicz5, Piotr Rhone6, Wojciech Jozwicki3
DOI: 10.5603/FHC.a2020.0022
·
Pubmed: 32960974
·
Folia Histochem Cytobiol 2020;58(3):198-207.
Affiliations
  1. Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw, Poland
  2. Department of Clinical Pathomorphology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland
  3. Department of Tumor Pathology and Pathomorphology, Department of Oncology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland, Torun, Poland
  4. Department of Human Biology, Institute of Biology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Torun, Poland
  5. Department of Oncology, The Franciszek Lukaszczyk Oncological Center, Bydgoszcz, Poland
  6. Department of Clinical Breast Cancer and Reconstructive Surgery, The Franciszek Lukaszczyk Oncological Center,, Bydgoszcz, Poland

open access

Vol 58, No 3 (2020)
ORIGINAL PAPERS
Submitted: 2020-03-19
Accepted: 2020-09-13
Published online: 2020-09-22

Abstract

Objectives. Ovarian cancer is a heterogeneous disease, with a number of different histological subtypes with various responses to treatment. Wilms’ tumor 1 (WT1) immunoreactivity is used to distinguish between OC’s various subtypes. However, little is known about the protein’s role as a prognostic factor. Thus, the main aim of our study was to evaluate the relationship between WT1 expression and patient overall survival (OS) and lymph node metastases. Materials and methods. Study group consisted of 164 women aged 22–84, diagnosed with epithelial ovarian cancer (EOC). WT1 expression in histological slides was assessed by immunohistochemistry. Results. Serous tumors were the most common subtype among EOC (n = 126; 76.8%), followed by endometrioid (n = 20; 12.2%), clear-cell (n = 14; 8.5%) and mucinous cancer (n = 4; 2.4%). Of all serous EOC, WT1-positive tumors accounted for 75.6% of cases and this number was significantly higher than in other histological subtypes (p < 0.0001). Patients with lymph node metastases were more likely to have WT1-positive than WT1-negative tumors (p = 0.006). There was no significant correlation between WT1 immunoreactivity and OS across the whole study group of EOC patients (p = 0.6); however, in the group of non-serous (mucinous, endometrioid and clear-cell) EOC subjects, WT1 immunoreactivity was associated with shorter OS (p = 0.046). Conclusions. WT1 immunoreactivity may be helpful in differentiating primary epithelial serous carcinomas from non-serous ovarian cancers; however, its prognostic role in EOC is rather uncertain.

Abstract

Objectives. Ovarian cancer is a heterogeneous disease, with a number of different histological subtypes with various responses to treatment. Wilms’ tumor 1 (WT1) immunoreactivity is used to distinguish between OC’s various subtypes. However, little is known about the protein’s role as a prognostic factor. Thus, the main aim of our study was to evaluate the relationship between WT1 expression and patient overall survival (OS) and lymph node metastases. Materials and methods. Study group consisted of 164 women aged 22–84, diagnosed with epithelial ovarian cancer (EOC). WT1 expression in histological slides was assessed by immunohistochemistry. Results. Serous tumors were the most common subtype among EOC (n = 126; 76.8%), followed by endometrioid (n = 20; 12.2%), clear-cell (n = 14; 8.5%) and mucinous cancer (n = 4; 2.4%). Of all serous EOC, WT1-positive tumors accounted for 75.6% of cases and this number was significantly higher than in other histological subtypes (p < 0.0001). Patients with lymph node metastases were more likely to have WT1-positive than WT1-negative tumors (p = 0.006). There was no significant correlation between WT1 immunoreactivity and OS across the whole study group of EOC patients (p = 0.6); however, in the group of non-serous (mucinous, endometrioid and clear-cell) EOC subjects, WT1 immunoreactivity was associated with shorter OS (p = 0.046). Conclusions. WT1 immunoreactivity may be helpful in differentiating primary epithelial serous carcinomas from non-serous ovarian cancers; however, its prognostic role in EOC is rather uncertain.

Get Citation

Keywords

epithelial ovarian cancer; WT1; Wilms’ tumor antigen 1; lymph node metastases

About this article
Title

Wilms’ tumor 1 antigen immunoreactivity in epithelial ovarian cancer — diagnostic and prognostic value

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 58, No 3 (2020)

Article type

Original paper

Pages

198-207

Published online

2020-09-22

DOI

10.5603/FHC.a2020.0022

Pubmed

32960974

Bibliographic record

Folia Histochem Cytobiol 2020;58(3):198-207.

Keywords

epithelial ovarian cancer
WT1
Wilms’ tumor antigen 1
lymph node metastases

Authors

Elzbieta Zarychta
Katarzyna Lepinay
Sebastian Szubert
Jakub Jozwicki
Jan Misiak
Anna A. Brozyna
Katarzyna Kosinska-Kaczynska
Agnieszka Lewandowska
Ewa Malicka
Adrianna Makarewicz
Piotr Rhone
Wojciech Jozwicki

References (29)
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Vecchia CLa. Ovarian cancer. Eur J Cancer Prev. 2017; 26(1): 55–62.
  3. Rizzuto I, Behrens RF, Smith LA, et al. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 2013; 6(8): CD008215.
  4. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4): 284–296.
  5. Şakirahmet Şen D, Gökmen Karasu AF, Özgün Geçer M, et al. Utilization of Wilms' tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas. Turk J Obstet Gynecol. 2016; 13(1): 37–41.
  6. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001; 73(2): 177–187.
  7. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 1990; 346(6280): 194–197.
  8. Charles AK, Mall S, Watson J, et al. Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study. Mol Pathol. 1997; 50(3): 138–144.
  9. Sagiyama H. WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy. Jpn J ClinOncol. 2010; 40(5): 377–87.
  10. Carter JH, Deddens JA, Mueller G, et al. Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer. Br J Cancer. 2018; 119(4): 462–470.
  11. Lu J, Gu Y, Li Q, et al. Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis. Medicine (Baltimore). 2018; 97(28): e11485.
  12. Pecorrelli S, Creasman WT, Pettersson F, et al. et al.. FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat. 1998; 3: 75–102.
  13. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000; 31(5): 539–557.
  14. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993; 71(2 Suppl): 606–614.
  15. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; 2(1): 3.
  16. Hylander B, Repasky E, Shrikant P, et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol. 2006; 101(1): 12–17.
  17. Rekhi B, Deodhar KK, Menon S, et al. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. APMIS. 2018; 126(1): 45–55.
  18. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004; 23(2): 110–118.
  19. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005; 36(2): 195–201.
  20. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002; 117(4): 541–545.
  21. Høgdall EVS, Christensen L, Kjaer SK, et al. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. Gynecol Oncol. 2007; 106(2): 318–324.
  22. Liu Z, Yamanouchi K, Ohtao T, et al. High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res. 2014; 34(5): 2331–2340.
  23. Rhodes A, Vallikkannu N, Jayalakshmi P. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer. Br J Biomed Sci. 2017; 74(2): 65–70.
  24. Yamamoto S, Tsuda H, Kita T, et al. Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch. 2007; 451(1): 27–35.
  25. Barbolina MV, Adley BP, Shea LD, et al. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer. 2008; 112(7): 1632–1641.
  26. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17): 5323–5337.
  27. Vermeij R, Daemen T, de Bock GH, et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol. 2010; 2010.
  28. Li G, Zeng Y, Chen X, et al. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol. 2007; 148(1): 136–145.
  29. Lu J, Gu Y, Li Q, et al. Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis. Medicine (Baltimore). 2018; 97(28): e11485.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl